Status:
COMPLETED
A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Lead Sponsor:
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
The main purpose of this study is to assess the safety and efficacy of LY4100511 in adult participants with moderate-to-severe plaque psoriasis.
Eligibility Criteria
Inclusion
- Clinical diagnosis of plaque psoriasis for 6 months before the baseline day 1 randomization
- Must have a body mass index (BMI) of 18 to 40 kilogram/square meter (kg/m2) (inclusive).
- Must be willing to discontinue topical and/or systemic therapies for psoriasis before the first dose of study intervention.
- Must agree to avoid prolonged exposure to the sun and to refrain from the use of tanning booths, sun lamps, and other sources of ultraviolet light during the study
Exclusion
- Have had a clinically significant flare of psoriasis during the 12 weeks before the baseline, as assessed by the investigator.
- Have a history of erythrodermic psoriasis, generalized or localized pustular psoriasis, predominantly guttate psoriasis, or medication-induced or medication-exacerbated psoriasis.
- Have any known or suspected diagnosis of inflammatory conditions other than psoriasis and psoriatic arthritis, including but not limited to rheumatoid arthritis, sarcoidosis, IBD (Crohn's disease or ulcerative colitis), or systemic lupus erythematosus.
- Have a diagnosis of psoriatic arthritis requiring, or are currently receiving, systemic immunosuppressant medical treatment (including corticosteroids, immunosuppressants, and biologics).
- Have a current or recent acute, active infection. Participant must have no symptoms or signs of confirmed or suspected infection and must have completed any appropriate anti-infective treatment for at least 30 days before screening and up to randomization/baseline.
Key Trial Info
Start Date :
October 25 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 4 2025
Estimated Enrollment :
222 Patients enrolled
Trial Details
Trial ID
NCT06602219
Start Date
October 25 2024
End Date
September 4 2025
Last Update
September 12 2025
Active Locations (58)
Enter a location and click search to find clinical trials sorted by distance.
1
Cahaba Dermatology Skin Health Center
Birmingham, Alabama, United States, 35244
2
Dermatology Trial Associates
Bryant, Arkansas, United States, 72022
3
Zenith Research, Inc.
Beverly Hills, California, United States, 90212
4
First OC Dermatology Research Inc
Fountain Valley, California, United States, 92708